At a Glance
11.2 Capital operates as a specialized deep-tech venture capital firm based in New York, focusing on the intersection of artificial intelligence, digital health, and cybersecurity since its 2018 founding. The firm distinguishes itself through an unusual dual-stage investment approach, participating in both pre-seed rounds for emerging startups and Series B+ funding for more mature companies, allowing them to maintain relationships with portfolio companies across multiple growth phases. Their bioengineering focus sets them apart in a crowded VC market, as few firms possess the technical expertise to evaluate complex biotech and medtech opportunities at the intersection of AI and life sciences. The firm's investment strategy appears centered on identifying companies that leverage artificial intelligence to solve fundamental problems in healthcare delivery, medical devices, and biotechnology applications. While 11.2 Capital maintains a relatively low public profile compared to larger institutional funds, industry observers note their selective approach to deal sourcing and emphasis on technical due diligence. The firm's New York location positions them strategically within the growing East Coast tech ecosystem, particularly for digital health companies that benefit from proximity to major medical institutions and regulatory expertise. Their portfolio construction suggests a focus on companies developing proprietary technology platforms rather than incremental software solutions, reflecting their deep-tech thesis. The cybersecurity component of their investment mandate typically intersects with their healthcare focus, targeting companies developing security solutions for medical data, IoT devices in healthcare settings, and compliance-focused enterprise software. Since inception, 11.2 Capital has operated with a concentrated portfolio approach, suggesting they prefer to make meaningful investments in fewer companies rather than pursuing a spray-and-pray strategy common among early-stage funds.
“Early-stage deep-tech investor with rare bioengineering focus, investing in AI, digital health, and cybersecurity.”
11.2 Capital appears to be operating from their initial fund raised following the firm's 2018 founding. As a relatively young firm, specific details about fund size, capital commitments, or performance metrics have not been publicly disclosed. The firm's investment activity suggests they have sufficient capital to participate meaningfully in both early-stage pre-seed rounds and larger Series B+ financings, indicating a fund size likely in the tens of millions rather than hundreds of millions typical of larger institutional funds.
David Dorsey
Partner, 11.2 Capital
Pramod Gosavi
Principal, 11.2 Capital
Shelley Zhuang
Founder and Managing Partner, 11.2 Capital
11.2 Capital primarily invests at the Pre-Seed, Series B+ stages. This means they focus on companies that are at the earliest idea or prototype phase.
11.2 Capital is headquartered in New York, NY. Many of their portfolio companies are also based in this region, though they invest across geographies.
11.2 Capital focuses on investments in AI, Digital Health, Cybersecurity. Their portfolio reflects deep expertise and networks within these sectors.
11.2 Capital's typical investment check size ranges from $500K to $3M. Actual amounts may vary based on the stage, sector, and specific opportunity.